STOCK TITAN

Galmed Pharmaceuticals Ltd. (GLMD) Stock Price, News & Analysis

GLMD NASDAQ

Ticker history: GLMD became EOCN (Eocene Ltd.) on .

Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
75 252 sessions, September 9, 2025 to September 9, 2026
Largest daily move
-32.6% close of June 8, 2026
1-year change
-60.2% closing prices, September 9, 2025 to September 9, 2026
1-month change
-3.8% closing prices, August 7, 2026 to September 9, 2026

Company Description

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company focused on the development of its lead drug candidate, Aramchol. According to the company’s disclosures, Galmed has focused almost exclusively on developing Aramchol for the treatment of liver disease, including non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), and liver fibrosis. More recently, Galmed describes itself as a clinical-stage biopharmaceutical company for liver, cardiometabolic, and gastrointestinal (GI) oncological indications, reflecting a broader development strategy built around Aramchol.

Galmed states that it is seeking to advance Aramchol for oncological indications outside of NASH and fibrosis, particularly in GI cancers. Company communications describe joint research with Virginia Commonwealth University (VCU) evaluating Aramchol’s effect on overcoming drug resistance in GI cancer models. In these studies, Aramchol has been evaluated in combination with Stivarga (regorafenib) and metformin in gastrointestinal tumor models, with reported top-line results that a three-drug combination significantly enhanced GI tumor cell killing in vivo and in vitro. These findings form the translational rationale for planned Phase 1/2 clinical studies in metastatic colorectal cancer (CRC), hepatocellular carcinoma (HCC) and cholangiocarcinoma.

Within liver disease, Galmed reports that Aramchol is a first-in-class, Phase 3-ready drug candidate that has been evaluated in multiple clinical trials, including the Phase 3 ARMOR study in MASH/NASH. The company highlights that Aramchol has shown fibrosis improvement and describes its safety and tolerability profile as excellent in advanced clinical studies. Galmed emphasizes Aramchol’s role as a down-regulator of stearoyl-CoA desaturase 1 (SCD1), and characterizes it as the most advanced SCD1 down-regulator in clinical development, based on its own development history and clinical program.

In addition to oral formulations, Galmed is developing new formulation technologies for Aramchol. The company has reported meaningful top-line results from its AM-001 Phase 1 bioavailability study of Aramchol meglumine, a granule formulation designed to improve bioavailability compared to Aramchol free acid tablets. In that study, Galmed reports that Aramchol meglumine granules achieved considerably greater bioavailability than the free acid tablets in healthy volunteers and that the pharmacokinetic profile supports a once-daily oral regimen. Galmed also notes work on a sublingual (SL) formulation of Aramchol to enable fixed-dose combinations for MASH, and a subcutaneous (SC) formulation aimed at achieving higher systemic exposure for cardiometabolic and cardiac indications.

Beyond NASH/MASH and oncology, Galmed describes a strategy to expand and diversify its pipeline by targeting cardiometabolic indications and other product candidates aligned with its drug development expertise. The company has announced the identification of a proprietary, blood-based pharmacodynamic biomarker signature for Aramchol, derived from plasma samples in the Phase 3 ARMOR study. This signature reportedly reflects reductions in systemic inflammation, oxidative stress and atherosclerotic drivers, as well as a decrease in atrial natriuretic peptide (ANP), a clinical marker associated with heart failure. Galmed states that this biomarker profile supports Aramchol’s potential multi-system therapeutic role in cardiometabolic and inflammatory conditions and may help guide future clinical development and regulatory discussions.

From a corporate perspective, Galmed is incorporated in Israel and files as a foreign private issuer with the U.S. Securities and Exchange Commission, furnishing periodic reports on Form 6-K and annual reports on Form 20-F. The company’s ordinary shares trade on The Nasdaq Capital Market under the ticker symbol GLMD. SEC filings indicate that Galmed operates through several wholly owned subsidiaries, including entities in Israel, Malta and the United Kingdom, all supporting its research and development activities around Aramchol.

Galmed’s public filings and press releases also describe a growth strategy that includes licensing, acquisitions and strategic operations. As part of this, the company has actively pursued opportunities to expand its product pipeline beyond Aramchol, including exploratory work on formulations such as a sublingual semaglutide product via a term sheet, and evaluation of a Self-Emulsifying Drug Delivery System (SEDDS) through a separate structure in which Galmed contemplates taking an equity stake rather than leading development. These activities are framed as complementary to its core focus on Aramchol and related cardiometabolic and GI oncology programs.

In addition to its drug development efforts, Galmed has adopted a digital asset management strategy as part of its treasury investment policy. The company has disclosed that its Board of Directors established a Crypto Committee to evaluate and, if appropriate, oversee crypto-related investing activities, including potential allocation of a portion of its cash reserves to digital assets. Galmed has entered into a non-binding letter of intent with Tectona Ltd., a specialized crypto treasury management service provider, to advise and help implement this digital asset strategy. The company characterizes this initiative as an effort to diversify its balance sheet and enhance capital efficiency, while maintaining liquidity to support its clinical and strategic plans.

Galmed’s SEC filings and press releases provide detailed financial information, including cash balances, research and development expenses, general and administrative expenses, and net losses over recent reporting periods. The company notes that it has raised capital through mechanisms such as at-the-market (ATM) offerings and share purchase agreements, and that it has increased its authorized share capital to provide flexibility for future capital raising and strategic transactions. These disclosures are intended to give investors insight into Galmed’s funding position as it advances Aramchol across liver, cardiometabolic and GI oncology indications.

Business focus and therapeutic areas

Across its communications, Galmed consistently describes itself as:

  • A biopharmaceutical company focused on the development of Aramchol.
  • Historically concentrated on liver diseases, particularly NASH/MASH and fibrosis.
  • Actively advancing Aramchol as a combination therapy candidate for MASH, including in combination with Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), supported by new use patents in multiple jurisdictions.
  • Seeking to develop Aramchol for oncological indications in GI cancers, including metastatic CRC, HCC and cholangiocarcinoma, often in combination with established standard-of-care agents.
  • Exploring cardiometabolic and broader metabolic-cardiovascular indications, supported by biomarker data and formulation work designed to increase systemic exposure.

Intellectual property and combination strategies

Galmed has highlighted intellectual property developments around Aramchol, particularly in the context of combination therapies. The company reports that it has obtained new use patents covering the combination of Aramchol with Rezdiffra (resmetirom) for the treatment of MASH and liver fibrosis in several territories, including the United States, Europe, Canada and South Korea. These patents are described as extending Aramchol’s patent protection for this combination into the 2040s and as strengthening its position in MASH combination therapy.

In oncology, Galmed has filed U.S. patent applications related to the combination of Aramchol with Stivarga (regorafenib) and metformin, based on preclinical data suggesting a synergistic effect and potential for a fixed-dose combination to address drug resistance in GI cancers. The company frames these IP efforts as part of a life-cycle management approach for both Aramchol and partnered standard-of-care agents.

Regulatory and reporting status

Galmed’s recent SEC filings on Form 6-K include unaudited interim condensed consolidated financial statements, updates on its clinical and preclinical programs, and descriptions of material corporate actions such as shareholder meetings and amendments to its Articles of Association. The company notes that, as a foreign private issuer, it is not required to file quarterly reports under Section 13 or 15(d) of the Securities Exchange Act, but furnishes interim reports as needed. These filings also incorporate by reference various registration statements on Form S-8 and Form F-3, which relate to equity compensation plans and potential securities offerings.

Risk and forward-looking considerations

Across its press releases and SEC reports, Galmed includes extensive forward-looking statements and risk factor disclosures. The company notes that its development programs for Aramchol in indications outside NASH/MASH and fibrosis, including oncology and cardiometabolic diseases, are subject to uncertainties related to clinical trial timing, cost, regulatory review by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), commercial launch, pricing, reimbursement, intellectual property protection, competition, financing needs and broader economic and geopolitical conditions. It also highlights specific risks associated with its digital asset management strategy, including the volatility of cryptocurrencies and other digital assets and potential correlations between its share price and digital asset prices.

Stock Performance

$4.63
No recent trading
Last close: September 9, 2026
-60.2%
1 year to September 9, 2026

Galmed Pharmaceuticals Ltd. (GLMD) closed at $4.63 on September 9, 2026. In the 12 months to September 9, 2026, the price lost 60.2%.

See what a $1,000 investment in GLMD was worth at its last close

GLMD Metrics & Rankings

Price returns through September 9, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Galmed Pharmaceuticals Ltd. has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include clinical trial, acquisition. View all GLMD news →

Financial Highlights

Galmed Pharmaceuticals Ltd. reported net income of -$10.3M in FY2025. Diluted earnings per share stood at $2.39. The company generated -$6.3M in operating cash flow. The current ratio was 6.55, measuring current assets divided by current liabilities.

-$10.3M
Net Income (FY2025)
-$6.3M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

Q3
2027
Q3 2027 Financial

Tiered earnout begins

Up-to $2.0M tiered earnout under Colospan acquisition begins; payments tied to CG-100 commercial milestones.
YEAR
2035
JUL
2042
July 2042 Corporate

U.S. Aramchol patent expiry

U.S. patent protection for Aramchol noted as extending through July 2042

Galmed Pharmaceuticals Ltd. has 3 upcoming scheduled events. The next event, "Tiered earnout begins", is expected in Q3 2027. 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the GLMD stock price.

Short Interest History

Last 12 Months

Short interest in Galmed Pharmaceuticals Ltd. (GLMD) currently stands at 19.6 thousand shares. A stock split fell inside this reporting period, so the figure cannot be compared with the previous one.

Days to Cover History

Last 12 Months

Days to cover for Galmed Pharmaceuticals Ltd. (GLMD) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume.

GLMD Company Profile & Sector Positioning

Galmed Pharmaceuticals Ltd. (GLMD) and is listed on the NASDAQ.

Investors comparing GLMD often look at related companies in the same sector, including Propanc Biopharma, Inc. (PPCB), Zymeworks Inc. (ZYME), Oric Pharmaceuticals, Inc. (ORIC), Eupraxia Pharmaceuticals Inc. (EPRX), and C4 Therapeutics, Inc. (CCCC). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate GLMD's relative position within its industry.

Frequently Asked Questions

Galmed Pharmaceuticals Ltd. (GLMD) has no recent trading. Its last close was $4.63 on September 9, 2026. The company now trades as EOCN.

The FY2025 net income of Galmed Pharmaceuticals Ltd. (GLMD) is -$10.3M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Galmed Pharmaceuticals Ltd. (GLMD) is $2.39 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Galmed Pharmaceuticals Ltd. (GLMD) is -$6.3M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Galmed Pharmaceuticals Ltd. (GLMD), current assets divided by current liabilities, was 6.55 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.